



## Deed of Release entered into with CEO

**17 June 2025:** As announced by Patrys Limited (ASX: PAB) (**Patrys** or the **Company**) on 10 June 2025, the position of Chief Executive Officer will be made redundant. The Company has now finalised the terms of the redundancy and has entered into a deed of release with its CEO and Managing Director, Dr James Campbell (**Deed of Release**).

The Deed of Release is on standard and customary terms. The key terms of the Deed of Release are as follows:

- CEO's employment will end on 1 July 2025;
- CEO will take leave without pay from 17 June 2025 to 30 June 2025;
- CEO is entitled to his accrued statutory leave entitlements, accrued unpaid salary, statutory redundancy payments, termination payments (including a payment in lieu of 6 months' notice), equalling approximately \$535,877 less applicable tax (**Entitlements**). Approximately 36% of the Entitlements are attributable to the payment in lieu of notice;
- To conserve cash in the Company, Dr Campbell has requested that approximately 43% of the Entitlements amounting to \$231,748 (less applicable tax) be satisfied by the issue of ordinary shares in the Company at an issue price of \$0.001 per share, subject to shareholder approval (**Redundancy Shares**);
- If shareholder approval is not obtained for the Redundancy Shares on or before 31 August 2025, the value of the Redundancy Shares will be paid as cash (subject to any limits required under the ASX Listing Rules);
- Dr Campbell will hold the position of non-executive director of the Company after 1 July 2025.

For further details of the proposed Redundancy Shares, please see the attached Appendix 3B.

As noted above, the issue of the Redundancy Shares is subject to shareholder approval at a general meeting of the Company. Further details will follow in a notice of general meeting to be issued by the Company in due course.

The release of this announcement was authorised by the Chair of Patrys Limited on behalf of the Board of Directors.

### For further information, please contact:

**General enquiries**  
Charmaine Gittleson  
Non-Executive Chair  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

**Media enquiries:**  
Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)

### Registered Office Address

Suite 2, Level 11  
385 Bourke Street  
Melbourne VIC 3000

### About Patrys Limited

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. More information can be found at [www.patrys.com](http://www.patrys.com).

For personal use only